Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko I, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen Y, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava M, Bennett E, Gitlitz B, Wakelee H, Investigators O. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. Journal Of Clinical Oncology 2025, 43: 2343-2349. PMID: 40446184, DOI: 10.1200/jco-24-01681.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease-free survivalPD-L1 TCCell lung cancerOverall survivalAdjuvant chemotherapySurvival outcomesResected stage IB-IIIA non-small cell lung cancerStage IB-IIIA non-small cell lung cancerTumor cellsResected non-small cell lung cancerFollow-upLung cancerFive-year survival outcomesStratified hazard ratioPlatinum-based chemotherapyStage II-IIIAPhase III trialsReport survival outcomesIntention-to-treatStratified HROpen-labelIII trialsAtezolizumabChemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply